Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
9.38
+0.06 (0.64%)
Mar 19, 2026, 4:00 PM EDT - Market closed
Vir Biotechnology Revenue
In the year 2025, Vir Biotechnology had annual revenue of $68.56M, down -7.61%. Vir Biotechnology had revenue of $64.07M in the quarter ending December 31, 2025, with 417.78% growth.
Revenue (ttm)
$68.56M
Revenue Growth
-7.61%
P/S Ratio
19.09
Revenue / Employee
$186,801
Employees
367
Market Cap
1.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 68.56M | -5.65M | -7.61% |
| Dec 31, 2024 | 74.21M | -11.98M | -13.90% |
| Dec 31, 2023 | 86.18M | -1.53B | -94.67% |
| Dec 31, 2022 | 1.62B | 520.38M | 47.51% |
| Dec 31, 2021 | 1.10B | 1.02B | 1,334.39% |
| Dec 31, 2020 | 76.37M | 68.28M | 843.86% |
| Dec 31, 2019 | 8.09M | -2.58M | -24.16% |
| Dec 31, 2018 | 10.67M | 7.96M | 293.94% |
| Dec 31, 2017 | 2.71M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Monte Rosa Therapeutics | 123.67M |
| Immatics | 56.67M |
| Zenas BioPharma | 10.00M |
| Taysha Gene Therapies | 9.77M |
| AtaiBeckley | 4.09M |
VIR News
- 21 days ago - Vir Biotechnology to Participate in Upcoming Investor Conferences - Business Wire
- 22 days ago - Vir Biotechnology Announces Pricing of Public Offering of Common Stock - Business Wire
- 23 days ago - Vir Biotechnology Announces Proposed Public Offering of Common Stock - Business Wire
- 23 days ago - Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish - Seeking Alpha
- 23 days ago - These Analysts Boost Their Forecasts On Vir Biotechnology - Benzinga
- 23 days ago - What's Happening With VIR Stock? - Forbes
- 24 days ago - Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire